prostate cancer

(redirected from Recurrent prostate cancer)
Also found in: Thesaurus, Medical, Encyclopedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.prostate cancer - cancer of the prostate gland
adenocarcinoma, glandular cancer, glandular carcinoma - malignant tumor originating in glandular epithelium
References in periodicals archive ?
MR-guided targeted focal and regional therapies are increasingly used for localised primary (native) and recurrent prostate cancer as well as for monitoring the effectiveness of these treatments.
A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.
Moreover, in the trial, which is evaluating ProscaVax for safety and tolerability in recurrent prostate cancer patients with increasing prostate specific antigen (PSA), no serious adverse events related to ProscaVax were reported, further validating ProscaVaxs safety profile.
The ASCENDE - RT Trial, which was published earlier this year, has shown 89% of men have no sign of recurrent prostate cancer at five years after their combination therapy.
Axumin is the first FDA-approved F18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer.
M2 PHARMA-June 7, 2016-Blue Earth Diagnostics, Siemens' Petnet Solutions Launch Axumin Injection for PET Imaging of Recurrent Prostate Cancer
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
The planned 100-patient clinical trial will be structured as a two-stage study of ProscaVax (PSA/IL-2/GM-CSF) for the treatment of PSA recurrent prostate cancer in hormone-naive and hormone-independent patients.
This study assesses biological activity of two doses of pomegranate extract (POMx) in men with recurrent prostate cancer, using changes in PSADT as the primary outcome.
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Study leader Dr William Figg, from the National Institutes of Health, in Bethesda, Maryland, US, said: "Thalidomide is associated with an increase in PSA progression-free survival in men with biochemically recurrent prostate cancer after intermittent ADT.

Full browser ?